2 New Melanoma Drugs and 1 Vaccine Acquisition

Before you go, we thought you'd like these...
Before you go close icon

Like all big pharmas reinventing themselves post patent cliff, GlaxoSmithKline is staying busy. It just received FDA approval for two new melanoma drugs and snatched up a Swiss vaccine company for roughly $325 million.

In this video, health-care analyst David Williamson discusses what these two big pieces of news mean for Glaxo investors and also for its competitors.

Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 


The article 2 New Melanoma Drugs and 1 Vaccine Acquisition originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners